Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-018897
Filing Date
2025-02-12
Accepted
2025-02-12 16:30:08
Documents
1
Period of Report
2025-02-11

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7563
  Complete submission text file 0000950170-25-018897.txt   9149
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Issuer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LINEAGE CELL THERAPEUTICS, INC. 2173 SALK AVENUE, SUITE 200 CARLSBAD CA 92008
Business Address
Samuel George A. III (Reporting) CIK: 0001878732 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-12830 | Film No.: 25615286